View Cart (0 items)

Pharmaceutical

Tighter restrictions to be placed on hydrocodone combination products

Medicines containing hydrocodone, a highly addictive painkiller, will be subject to more restrictions under new rules published by the U.S. Drug Enforcement Administration (DEA) this week.
Read More

FDA warns consumers to avoid fraudulent Ebola treatment products

The agency said that it had seen and received consumer complaints about various products being offered online that are claimed to either prevent the Ebola virus or treat the infection.
Read More

Sanofi, MannKind agree on $925 million deal for inhaled insulin therapy

Under the exclusive agreement with MannKind Corporation the two companies will collaborate on development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.
Read More

Alvogen acquires South Korea's Dream Pharma

Pharmaceutical company Alvogen has agreed to purchase Dream Pharma, based in South Korea, for $187 million in cash.
Read More

US pharmaceutical packaging products market valued at $22.1 billion

U.S. demand for pharmaceutical packaging products is expected to increase slightly in the next few years as drug makers upgrade the barrier, security and functional properties of their packaging systems.
Read More

FDA reveals details on generic drugs watchdog reorganization

The U.S. Food and Drug Administration (FDA) has announced details of its long-awaited reorganization of the Office of Generic Drugs (OGD).
Read More

Mylan Buys Abbott's Non-U.S. Generic Drugs Portfolio

The deal will cost an estimated $5.3 billion and involve more than 100 products in several key areas.
Read More

Salix Pharmaceuticals to merge with Cosmo subsidiary

U.S.-based Salix Pharmaceuticals Ltd. has announced plans to merge with a unit of Italian company Cosmo Pharmaceuticals, Cosmo Technologies Ltd.
Read More

Omnicare to pay $124 million to settle fraud allegations

Cincinnati-based Omnicare Inc. is to pay more than $124 million in a settlement with the U.S. Department of Justice for allegedly offering financial incentives to healthcare facilities.
Read More

US regulator to tighten scrutiny on potential drug delay deals

The U.S. Federal Trade Commission has announced plans to increase probes into pharmaceutical deals that potentially harm competition by delaying the launch of generic drugs on the market.
Read More